Abstract
Syntheses of thirty 2,4,6-trichlorophenylhydrazine Schiff bases 1-30 were carried out and evaluated for their in vitro DPPH radical and super oxide anion scavenging activities. Compounds 1-30 have shown a varying degree of DPPH radical scavenging activity and their IC50 values range between 4.05-369.30 µM. The compounds 17, 28, 18, 14, 8, 15, 12, 2, 29, and 7 exhibited IC50 values ranging between 4.05 ± 0.06-24.42 ± 0.86 µM which are superior to standard n-propylgallate (IC50 = 30.12 ± 0.27 µM). Selected compounds have shown a varying degree of superoxide anion radical scavenger activity and their IC50 values range between 91.23-406.90 µM. The compounds 28 8, 17, 15, and 14, showed IC50 values between 91.23 ± 1.2-105.31 ± 2.29 µM which are superior to standard n-propylgallate (IC50 = 106.34 ± 1.6 µM).
Keywords: 2, 4, 6-Trichlorophenylhydrazine Schiff bases, DPPH radical, superoxide anion scavengers, trichlorophenylhydrazine, radical scavenging, propylgallate, antituberculosis, antifungal, rodenticides
Medicinal Chemistry
Title:2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers
Volume: 8 Issue: 3
Author(s): Khalid Mohammed Khan, Zarbad Shah, Viqar Uddin Ahmad, Momin Khan, Muhammad Taha, Fazal Rahim, Sajjad Ali, Nida Ambreen, Shahnaz Perveen, M. Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: 2, 4, 6-Trichlorophenylhydrazine Schiff bases, DPPH radical, superoxide anion scavengers, trichlorophenylhydrazine, radical scavenging, propylgallate, antituberculosis, antifungal, rodenticides
Abstract: Syntheses of thirty 2,4,6-trichlorophenylhydrazine Schiff bases 1-30 were carried out and evaluated for their in vitro DPPH radical and super oxide anion scavenging activities. Compounds 1-30 have shown a varying degree of DPPH radical scavenging activity and their IC50 values range between 4.05-369.30 µM. The compounds 17, 28, 18, 14, 8, 15, 12, 2, 29, and 7 exhibited IC50 values ranging between 4.05 ± 0.06-24.42 ± 0.86 µM which are superior to standard n-propylgallate (IC50 = 30.12 ± 0.27 µM). Selected compounds have shown a varying degree of superoxide anion radical scavenger activity and their IC50 values range between 91.23-406.90 µM. The compounds 28 8, 17, 15, and 14, showed IC50 values between 91.23 ± 1.2-105.31 ± 2.29 µM which are superior to standard n-propylgallate (IC50 = 106.34 ± 1.6 µM).
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Shah Zarbad, Uddin Ahmad Viqar, Khan Momin, Taha Muhammad, Rahim Fazal, Ali Sajjad, Ambreen Nida, Perveen Shahnaz, Iqbal Choudhary M. and Voelter Wolfgang, 2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/1573406411208030452
DOI https://dx.doi.org/10.2174/1573406411208030452 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021
CNS & Neurological Disorders - Drug Targets Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Prediabetic Dysglycemia: Call for Action
Current Diabetes Reviews The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design The Involvement of Uric Acid in the Pathogenesis of Preeclampsia
Current Hypertension Reviews Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Subject Index To Volume 12
Current Pharmaceutical Design Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research